Cough hypersensitivity and chronic cough

KF Chung, L McGarvey, WJ Song, AB Chang… - Nature Reviews …, 2022 - nature.com
Chronic cough is globally prevalent across all age groups. This disorder is challenging to
treat because many pulmonary and extrapulmonary conditions can present with chronic …

Idiopathic pulmonary fibrosis: Current and future treatment

DS Glass, D Grossfeld, HA Renna… - The clinical …, 2022 - Wiley Online Library
Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

Treatment of fibrotic interstitial lung disease: current approaches and future directions

KA Johannson, N Chaudhuri, A Adegunsoye… - The Lancet, 2021 - thelancet.com
Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that
are often progressive and associated with high morbidity and early mortality. Important …

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: a position statement from the Thoracic …

AS Jee, R Sheehy, P Hopkins, TJ Corte… - …, 2021 - Wiley Online Library
Pulmonary complications in CTD are common and can involve the interstitium, airways,
pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from …

Publisher correction: sarcoidosis

J Grunewald, JC Grutters, EV Arkema… - Nature Reviews …, 2019 - search.proquest.com
Publisher Correction: Sarcoidosis Johan Grunewald, Jan C. Grutters, Elizabeth
V. Arkema, Lesley Ann Saketkoo, David R. Moller and Joachim M ller …

Thalidomide-revisited: are COVID-19 patients going to be the latest victims of yet another theoretical drug-repurposing?

A Khalil, A Kamar, G Nemer - Frontiers in immunology, 2020 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic is a worldwide threatening health
issue. The progression of this viral infection occurs in the airways of the lungs with an …

[HTML][HTML] Cough in chronic lung disease: a state of the art review

B Hirons, K Rhatigan, H Kesavan… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Chronic cough (CC;≥ 8 weeks in duration) is a common and burdensome feature of
respiratory diseases. The understanding of cough has progressed significantly in recent …

Development and initial validation analyses of the living with idiopathic pulmonary fibrosis questionnaire

JJ Swigris, DA Andrae, T Churney… - American Journal of …, 2020 - atsjournals.org
Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in development.
Tools are needed to assess whether these drugs benefit patients on outcomes that matter …

Holistic management of patients with progressive pulmonary fibrosis

A Oliveira, G Fabbri, T Gille, E Bargagli… - Breathe, 2023 - Eur Respiratory Soc
Progressive pulmonary fibrosis (PF) is a complex interstitial lung disease that impacts
substantially on patients' daily lives, requiring personalised and integrated care. We …

Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis: a randomized controlled crossover trial

SA Guler, C Clarenbach, M Brutsche… - Annals of the …, 2021 - atsjournals.org
Rationale: Patients with idiopathic pulmonary fibrosis (IPF) frequently suffer from chronic
cough that is difficult to treat, which substantially affects their quality of life. Azithromycin has …